Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Metagenomi Therapeutics, Inc. is a biotechnology company focused on developing next-generation genetic medicines using programmable nucleases derived from microbial genomes. The company operates within the biotechnology and genomic medicine industries, with a primary emphasis on gene editing technologies designed to enable precise and potentially curative treatments for patients with serious diseases. Its core value proposition lies in discovering and engineering novel gene-editing enzymes that can overcome limitations of first-generation CRISPR-Cas systems.
Metagenomi’s primary business centers on its proprietary gene-editing platform, which identifies compact and diverse nucleases capable of targeting a broad range of genomic sites. These technologies support in vivo gene editing approaches across therapeutic areas such as liver disease, ophthalmology, and immunology. Founded in 2016, the company evolved from a discovery-stage platform into a clinical-stage organization and became a publicly traded company following its initial public offering in 2024.
Business Operations
Metagenomi operates through a single integrated business model that combines enzyme discovery, protein engineering, and therapeutic development. Its revenue model historically has included collaboration and licensing agreements, while its current focus is on advancing wholly owned therapeutic programs toward clinical development. The company’s operations are centered on its proprietary gene editing platform, which leverages metagenomic data and machine learning to identify and optimize novel nucleases.
The company conducts research and development primarily in the United States, with laboratory and corporate operations supporting preclinical and early clinical programs. Metagenomi has established strategic collaborations with large pharmaceutical companies to apply its technologies in specific disease areas, while retaining rights to key internal programs. Data on certain partnership economics and downstream revenue potential is limited, and some disclosures remain program-dependent.
Strategic Position & Investments
Metagenomi’s strategic direction emphasizes building a differentiated pipeline of in vivo gene-editing therapeutics while expanding the capabilities of its enzyme discovery engine. Growth initiatives include advancing lead programs into clinical trials, expanding delivery technologies, and selectively partnering non-core assets to fund internal development. The company has invested significantly in protein engineering, bioinformatics, and high-throughput screening to strengthen its competitive position.
A major strategic milestone was its collaboration with Moderna, Inc., which provided validation of its platform and non-dilutive capital to support research activities. Metagenomi does not operate as a holding company and does not maintain a broad portfolio of equity investments; instead, it focuses capital deployment on internal R&D and platform expansion. Emerging areas of interest include compact nucleases suitable for lipid nanoparticle delivery and next-generation editing modalities.
Geographic Footprint
Metagenomi’s operations are primarily based in North America, with its headquarters and principal research facilities located in California, United States. The company’s workforce, laboratory infrastructure, and executive leadership are largely centralized in the U.S., reflecting its focus on domestic R&D activities.
While Metagenomi does not maintain significant owned international facilities, its strategic collaborations and scientific partnerships provide global reach, particularly through multinational pharmaceutical partners. Its technologies are intended for global therapeutic markets, though commercial operations outside the U.S. have not yet been established.
Leadership & Governance
Metagenomi is led by an experienced management team with backgrounds in biotechnology, pharmaceuticals, and genomics. The leadership emphasizes a science-driven culture, disciplined capital allocation, and long-term value creation through platform innovation and clinical execution.
Key executives include:
- Brian C. Thomas, Ph.D. – Chief Executive Officer
- Mark J. DeYoung, Ph.D. – Chief Scientific Officer
- Christine H. Kim – Chief Financial Officer
- Erin M. Harris, Ph.D. – Chief Operating Officer
- Robert D. Brown – Chief Legal Officer and Corporate Secretary
The company is governed by a board of directors with expertise spanning drug development, finance, and corporate governance, consistent with public biotechnology company standards.